Long Covid-19
72
14
18
36
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 72 trials
100.0%
+13.5% vs benchmark
6%
4 trials in Phase 3/4
14%
5 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (72)
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
AT1001 for the Treatment of Long COVID
Chronic-disease Self-management Program in Patients Living With Long-COVID in Puerto Rico
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms
RECOVER-ENERGIZE Platform Protocol_Appendix B (Structured Pacing (PEM))
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
Understanding the Long-term Impact of COVID-19 in Adults
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
RECOVER-AUTONOMIC Platform Protocol
RECOVER-SLEEP: Platform Protocol
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
Long COVID-19 Intervention (COVIDL/MIQoL)